A5067299217- Sarcoma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Cancer therapeutics and mechanisms
- Childhood Cancer Survivors' Quality of Life
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Bone Tumor Diagnosis and Treatments
- Acute Myeloid Leukemia Research
- Epigenetics and DNA Methylation
- Testicular diseases and treatments
- Cancer Diagnosis and Treatment
- Oral and Maxillofacial Pathology
- Neonatal Health and Biochemistry
- Management of metastatic bone disease
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Glioma Diagnosis and Treatment
- Cardiac tumors and thrombi
- Chronic Myeloid Leukemia Treatments
- Oral Health Pathology and Treatment
- Neutropenia and Cancer Infections
- Histone Deacetylase Inhibitors Research
- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- Eosinophilic Disorders and Syndromes
Dalhousie University
2009-2022
Izaak Walton Killam Health Centre
2012-2022
University of Louisville
1982-2020
University of Louisville Hospital
1980-2018
University of Colorado Anschutz Medical Campus
2018
Helios Hospital Berlin-Buch
2015
Klinikum Stuttgart
2015
Helios Klinikum Emil von Behring
2015
Institut Gustave Roussy
2015
Université Paris-Sud
2015
To compare three-drug chemotherapy with cisplatin, doxorubicin, and methotrexate four-drug methotrexate, ifosfamide for the treatment of osteosarcoma. determine whether addition muramyl tripeptide (MTP) to enhances event-free survival (EFS) overall in newly diagnosed patients osteosarcoma.Six hundred sixty-two osteosarcoma without clinically detectable metastatic disease whose was considered resectable received one four prospectively randomized treatments. All identical cumulative doses...
To determine whether the addition of ifosfamide and/or muramyl tripeptide (MTP) encapsulated in liposomes to cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) could improve probability for event-free survival (EFS) newly diagnosed patients with osteosarcoma (OS).Six hundred seventy-seven OS without clinically detectable metastatic disease were treated one four prospectively randomized treatments. All received identical cumulative doses HDMTX underwent definitive surgical resection...
High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults. The European American Osteosarcoma Study (EURAMOS)-1 collaboration of four study groups aiming to improve outcomes this rare disease by facilitating randomised controlled trials.Patients eligible for EURAMOS-1 were aged ≤40 years with M0 or M1 skeletal high-grade in which case complete surgical resection at all sites was deemed be possible. A three-drug combination methotrexate, doxorubicin...
We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response preoperative (≥10% viable tumour) improved event-free survival in with high-grade osteosarcoma.EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting newly diagnosed, resectable, osteosarcoma aged 40 years or younger were eligible randomisation. Patients randomly assigned (1:1) receive either cisplatin,...
EURAMOS-1, an international randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (IFN-α-2b) in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy.
The Ewing sarcoma family of tumors (ESFT) is a group malignant soft tissue and bone sharing chromosomal translocation affecting the EWS locus. Intergroup INT-0091 demonstrated superiority regimen vincristine, cyclophosphamide, doxorubicin (VDC), dactinomycin alternating with ifosfamide etoposide (IE) over VDC for patients nonmetastatic ESFT bone. goal this study was to determine whether dose-intensified IE would further improve outcome or tissue.Patients previously untreated, were eligible....
Four international study groups undertook a large in resectable osteosarcoma, which included two randomised controlled trials, to determine the effect on survival of changing post-operative chemotherapy based histological response.Patients with osteosarcoma aged ≤40 years were treated MAP regimen, comprising pre-operatively 5-week cycles cisplatin 120 mg/m(2), doxorubicin 75 methotrexate 12 g/m(2) × 2 (MAP) and post-operatively further just MA. Patients after surgery. Those ≥10% viable...
Despite efforts to intensify chemotherapy, survival for patients with metastatic osteosarcoma remains poor. Overexpression of human epidermal growth factor receptor 2 (HER2) in has been shown predict poor therapeutic response and decreased survival. This study tests the safety feasibility delivering biologically targeted therapy by combining trastuzumab standard chemotherapy HER2 overexpression.Among 96 evaluable newly diagnosed osteosarcoma, 41 had tumors that were HER2-positive...
Neuroblastoma, the most common extracranial solid tumor that occurs in early childhood, can be identified preclinical stages by detection of catecholamines urine. However, it is unknown whether routine screening for neuroblastoma reduces mortality due to this disease.
PURPOSE: To determine the response rate of combination cyclophosphamide and topotecan in pediatric patients with recurrent or refractory malignant solid tumors. PATIENTS AND METHODS: A total 91 patients, 83 whom were fully assessable for toxicity, received (250 mg/m 2 /dose) followed by (0.75 /dose), each given as a 30-minute infusion daily 5 days. All filgrastim (5 mcg/kg) until absolute neutrophil count (ANC) was ≥ 1,500 μL after time expected ANC nadir. RESULTS: 307 treatment courses to...
Purpose Nelarabine (compound 506U78), a water soluble prodrug of 9-b-d-arabinofuranosylguanine, is converted to ara-GTP in T lymphoblasts. We sought define the response rate nelarabine children and young adults with refractory or recurrent T-cell disease. Patients Methods performed phase II study patients stratified as follows: stratum 1: ≥ 25% bone marrow blasts first relapse; 2: second 3: positive CSF; 4: extramedullary (non-CNS) relapse. The initial dose was 1.2 g/m 2 daily for 5...
Abstract Background Imatinib mesylate is a small molecule inhibitor of certain tyrosine kinases, most notably the chimeric bcr‐abl fusion protein found in CML. It also inhibits KIT and PDGF receptor kinases vitro. Ewing sarcoma, osteosarcoma, neuroblastoma, desmoplastic round cell, synovial sarcomas often overexpress or receptor. A phase II study imatinib children young adults with select solid tumors was performed. Procedure Patients less than 30 years age refractory recurrent GIST were...
One hundred seventy-five cementless femoral hip revision surgeries with extensively porous-coated stems and 161 concomitant acetabular revisions done from 1984 to 1991 were retrospectively reviewed. Average age at surgery was 62.4 years. Followup ranged 2 10 years (average, 5 years). sixty-eight components (96%) remain in place. Two unstable components, 1 stable fibrous component, bone ingrowth component painful required rerevision. removed as part of resection arthroplasties for repetitive...
Abstract BACKGROUND. Effective chemotherapy is lacking for most types of central nervous system (CNS) tumors in children. Temozolomide, an agent with activity against adult brain tumors, was investigated children and adolescents recurrent CNS tumors. METHODS. Temozolomide administered orally as monthly 5‐day courses at doses 200 mg/m 2 /d (patients no prior craniospinal irradiation [CSI]) or 180 (prior CSI). Patients a complete (CR) partial (PR) response stable disease (SD) could continue...
Abstract Background The prognosis for patients with recurrent Ewing sarcoma (EWS) is very poor 5‐year survival of 13%. Methods To evaluate prognostic factors these we studied initially treated on the multi‐institutional study INT0091. Results Two hundred sixty‐two experienced disease recurrence. median time to first recurrence was 1.3 years (0–7.4 years), 1.4 years) localized and 1 year (0–6 metastatic disease. Time from date initial diagnosis a predictor post‐recurrence ( P < 0.0001)....
BACKGROUND: Although the frequency of complications in adults undergoing therapeutic apheresis is low, there are little data children. STUDY DESIGN AND METHODS: A retrospective study 186 children who had undergone a total 1632 procedures between 1994 and 2002 was conducted. Adverse reactions were prospectively documented. The plasma exchange (67%), hematopoietic progenitor cell collection (18%), red blood (6.9%), leukodepletion (0.7%), with immunoadsorption (6.7%). RESULTS: reactions, most...
BACKGROUND Patients with Ewing sarcoma require local primary tumor control surgery, radiation, or both. The optimal choice of for overall and disease remains unclear. METHODS localized bone who were treated on 3 consecutive protocols standard‐dose, 5‐drug chemotherapy every weeks included (n=465). Propensity scores used to differences between groups by constructing multivariate models assess the impact type clinical endpoints (event‐free survival [EFS], survival, failure, distant failure)...
Abstract Despite successful primary tumor treatment, the development of pulmonary metastasis continues to be most common cause mortality in patients with osteosarcoma. A conventional drug path requiring drugs induce regression established lesions has not led improvements for osteosarcoma more than 30 years. On basis our growing understanding biology, it is now reasonable and essential that we focus on developing therapeutics target metastatic progression. To advance this agenda, a meeting...
The impact of the modality used for local control Ewing sarcoma is uncertain. We investigated relationship between type modality, surgery, radiation (RT) or both (S + RT), and subsequent risk failure (LF) in patients with nonmetastatic pelvic treated on INT-0091.Patients < = 30 years sarcoma, primitive neuroectodermal tumor bone were randomly assigned to receive chemotherapy doxorubicin, vincristine, cyclophosphamide, dactinomycin, (VACA) these four drugs alternating ifosfamide etoposide...